{"id":1482,"date":"2022-04-21T08:32:33","date_gmt":"2022-04-21T06:32:33","guid":{"rendered":"http:\/\/serveur\/~onco-na\/?p=1482"},"modified":"2022-05-05T16:29:26","modified_gmt":"2022-05-05T14:29:26","slug":"meningiome","status":"publish","type":"post","link":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/?p=1482","title":{"rendered":"M\u00e9ningiome"},"content":{"rendered":"<div class=\"pdfprnt-buttons pdfprnt-buttons-post pdfprnt-top-right\"><a href=\"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fposts%2F1482&print=pdf\" class=\"pdfprnt-button pdfprnt-button-pdf\" target=\"_blank\" ><img decoding=\"async\" src=\"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/wp-content\/plugins\/pdf-print\/images\/pdf.png\" alt=\"image_pdf\" title=\"Afficher le PDF\" \/><\/a><a href=\"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fposts%2F1482&print=print\" class=\"pdfprnt-button pdfprnt-button-print\" target=\"_blank\" ><img decoding=\"async\" src=\"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/wp-content\/plugins\/pdf-print\/images\/print.png\" alt=\"image_print\" title=\"Contenu imprim\u00e9\" \/><\/a><\/div><table>\n<tbody>\n<tr>\n<th>Pr\u00e9cisions localisation<\/th>\n<th>Phase et Type d\u2019agent<\/th>\n<th>Principaux crit\u00e8res cliniques<\/th>\n<th>Contacts r\u00e9f\u00e9rents<\/th>\n<\/tr>\n<tr>\n<td>M\u00e9ningiome<\/td>\n<td>Phase I (escalade de dose)<\/p>\n<p>Tram\u00e9tinib + alpelisib<\/td>\n<td>\n<ul>\n<li>M\u00e9ningiome de grade II et III histologiquement prouv\u00e9\n<\/li>\n<li> Progression d\u00e9finie par une progression de la surface du m\u00e9ningiome de \u2265 10% en 3 mois ou \u2265 20% en 6 mois\n<\/li>\n<li> Echec de la chirurgie et pas de nouvelle chirurgie envisageable\n<\/li>\n<li> Echec de la radioth\u00e9rapie et\/ou radiochirurgie\n<\/li>\n<li> Chimioth\u00e9rapies, hormonoth\u00e9rapies ou traitements anti-VEGF ant\u00e9rieurs autoris\u00e9s si la progression sous l\u2019agent cytotoxique est document\u00e9e\n<\/li>\n<li> Wash-out de 4 semaines minimum\n<\/li>\n<li> IK > 50%<\/li>\n<\/ul>\n<\/td>\n<td>\n<ul style='list-style-type: none;'>\n<li><b>CHU de Bordeaux<\/b><\/li>\n<li>\nM\u00e9decin investigateur<\/li>\n<li> <a href=\"mailto:charlotte.bronnimann@chu-bordeaux.fr?subject=Site essais pr\u00e9coces\">charlotte.bronnimann@chu-bordeaux.fr<\/a><\/li>\n<li>\nARC<\/li>\n<li>\n<a href=\"mailto:delphine.pedenon@chu-bordeaux.fr?subject=Site essais pr\u00e9coces\">delphine.pedenon@chu-bordeaux.fr<\/a><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Pr\u00e9cisions localisation Phase et Type d\u2019agent Principaux crit\u00e8res cliniques Contacts r\u00e9f\u00e9rents M\u00e9ningiome Phase I (escalade de dose) Tram\u00e9tinib + alpelisib M\u00e9ningiome de grade II et&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[74],"tags":[],"class_list":["post-1482","post","type-post","status-publish","format-standard","hentry","category-meningiome"],"_links":{"self":[{"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=\/wp\/v2\/posts\/1482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1482"}],"version-history":[{"count":1,"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=\/wp\/v2\/posts\/1482\/revisions"}],"predecessor-version":[{"id":1532,"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=\/wp\/v2\/posts\/1482\/revisions\/1532"}],"wp:attachment":[{"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}